Botanically-derived Compound(s)
Major Depressive Disorder (MDD)
Key Facts
About ABVC BioPharma
ABVC BioPharma's mission is to develop and commercialize novel therapeutics derived from botanical compounds and synthetic molecules. Its key achievements include advancing multiple assets into clinical trials for conditions like Major Depressive Disorder (MDD), ADHD, and various solid tumors. The company's strategy leverages both internal R&D and external academic collaborations to navigate the capital-intensive drug development pathway, aiming to create value through clinical milestones and potential partnerships.
View full company profileAbout ABVC BioPharma
ABVC BioPharma's mission is to develop and commercialize novel therapeutics derived from botanical compounds and synthetic molecules. Its key achievements include advancing multiple assets into clinical trials for conditions like Major Depressive Disorder (MDD), ADHD, and various solid tumors. The company's strategy leverages both internal R&D and external academic collaborations to navigate the capital-intensive drug development pathway, aiming to create value through clinical milestones and potential partnerships.
View full company profileTherapeutic Areas
Other Major Depressive Disorder (MDD) Drugs
| Drug | Company | Phase |
|---|---|---|
| AL001 | Alzamend Neuro | Preclinical |
| Deep TMS (H1 Coil) | BrainsWay | FDA Cleared |
| EXXUA™ (gepirone ER) | Aytu BioPharma | Commercial |
| INV-202 (Oral & LAI) | Indivior | Preclinical |
| NeuroStar Advanced Therapy | Neuronetics | FDA Cleared |
| Gepirone ER | Fabre-Kramer Pharmaceuticals | NDA Submitted |
| Exablate Neuro | Insightec | Clinical Trial |
| BrightKaire Platform for Depression | NeuroKaire | Pre-clinical |
| Tyemvers (CKDB-501) | Healis Therapeutics | Pre-clinical |
| VENTURA-7 | New Hope Clinical Research | Phase 2/3 |
| DT-101 | Draig Therapeutics | Phase 2 |
| Major Depressive Disorder Program | Actipulse Neuroscience | Phase 3 |